Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: Multicenter study

Multiple Sclerosis

Volumn 14, Issue 1, 2008, Pages 73-80

  Sajja, B R ^a   Narayana, Ponnada A ^a   Wolinsky, J S ^a   Ahn, C W ^a   Brooks, William M ^b   Ford, Corey ^c   Richards, Todd ^d   Bowen, James ^d   Lindsey, J William ^a   Boulanger, Yvan ^e   Duquette, Pierre ^e   Arnold, Douglas L ^f  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Glatiramer acetate; MRI; MRSI; N acetylaspartate; Primary progressive multiple sclerosis; Proton spectroscopic imaging

Indexed keywords

CHOLINE; CREATINE; GLATIRAMER; LIPID; N ACETYLASPARTIC ACID; PLACEBO; ASPARTIC ACID; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; N-ACETYLASPARTATE; PEPTIDE; PROTON; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TISSUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; GRAY MATTER; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SPECTROSCOPY; WHITE MATTER; BRAIN; LONGITUDINAL STUDY; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; THEORETICAL MODEL;

ASPARTIC ACID; BRAIN; CHOLINE; CREATINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, THEORETICAL; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PEPTIDES; PROTONS;

EID: 42149098368     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507079907     Document Type: Article

References (24)

1. Thompson AJ, Polmann CH, Miller DH, McDonald WI, Brochet B, Fillip M et al. Primary progressive multiple sclerosis. Brain 1997; 120: 1085-96.
2. Rovaris M, Gallo A, Falini A, Benedetti B, Rossi P, Comola M et al. Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. Arch Neurol 2005; 62: 898-902.
3. Narayana PA, Wolinsky JS, Rao SB, He R, Mehta M, the PROMiSe Trial MRSI Group. Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis. Mult Scler 2004; 10: S73-78.
4. 1H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings. Eur Radiol 2006; 16: 489-95.
5. Filippi M, Iannucci G, Tortorella C. Minicucci L, Horsfield MA, Colombo B et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 1999; 52: 588-94.
6. 1H MR spectroscopy and diffusion tensor imaging. Eur Radiol 2005; 15: 1686-93.
7. Narayana PA. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 2005; 15(4 Suppl): 46S-57S.
8. Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999; 20: 1619-27.
9. Sastre-Garriga J, Ingle GT, Chard DT, Ramio-Torrenta L, McLean MA, Miller DH et al. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol 2005; 62: 569-73.
10. Caramanos Z, Santos AC, Francis SJ, Narayanan S, Pelletier D, Arnold DL. Proton magnetic resonance spectroscopy. In Fillip M, Comi G eds. Primary progressive multiple sclerosis. Springer Verlag, 2002: 89-112.
11. Basile E, Gibbs E, Aziz T, Oger J. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. J Neuroimmunol 2006; [Epub ahead of print].
12. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double blinded, placebo-controlled trial. The copolymer 1 multiple sclerosis group. Neurology 1995; 45: 1268-76.
13. Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K et al. Glatiramer acetate in primary progressive multiple sclerosis: result of a multinational, multicenter, double-blind placebo-controlled trail. Ann Neurol 2007; 61: 14-24.
14. Bedell BJ, Narayana PA, Wolinsky JS. A dual approach for minimizing false lesion classifications on magnetic resonance images. Magn Reson Med 1997; 37: 94-102.
15. Kuhn B, Dreher W, Norris DG, Leibfritz D. Fast proton spectroscopic imaging employing k-space weighting achieved by variable repetition times. Magn Reson Med 1996; 35: 457-64.
16. Yu H, Narayana PA. Quantitative comparison of variable and constant repetition time proton spectroscopic imaging. Proceedings of the International Society for Magnetic Resonance in Medicine Eighth Scientific Meeting, Denver, CO, 1-7 April 2000: 427.
17. Doyle TJ, Pathak R, Wolinsky JS, Narayana PA. Automated proton spectroscopic image processing. J Magn Reson B 1995; 106: 58-63.
18. 1H-CSI. Magn Reson Med 1993; 30: 277-82.
19. Bhat H, Sajja BR, Narayana PA. Fast quantification of proton magnetic resonance spectroscopic imaging with artificial neural networks. J Magn Reson 2006; 183: 110-22.
20. Zeger SL, Liang KV, Albert PS. Models for longitudinal data: A generalized estimating equation appraoch. Biometrics 1988; 44: 1049-60.
21. Mierisová Š, Ala-Korpela M. MR spectroscopy quantitation: a review of frequency domain methods. NMR Biomed 2001; 14: 247-59.
22. Wolinsky JS. The use of glatiramer acetate in the treatment of multiple sclerosis. Adv Neurol 2006; 98: 273-92.
23. Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifroni G, Wolinsky JS et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006; 12: 309-20.
24. Khan O, Shen Y, Caon C, Bao F, Ching W, Reznar M et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2005; 11: 646-51.